Evotec AG (NASDAQ:EVO) Short Interest Update
by Amy Steele · The Cerbat GemEvotec AG (NASDAQ:EVO – Get Free Report) saw a significant growth in short interest in the month of February. As of February 27th, there was short interest totaling 352,335 shares, a growth of 36.3% from the February 12th total of 258,431 shares. Based on an average daily trading volume, of 112,820 shares, the days-to-cover ratio is presently 3.1 days. Currently, 0.1% of the company’s shares are short sold. Currently, 0.1% of the company’s shares are short sold. Based on an average daily trading volume, of 112,820 shares, the days-to-cover ratio is presently 3.1 days.
Analysts Set New Price Targets
A number of analysts recently weighed in on the company. Wall Street Zen upgraded Evotec from a “sell” rating to a “hold” rating in a report on Saturday, January 10th. Berenberg Bank assumed coverage on Evotec in a research report on Tuesday, February 3rd. They issued a “buy” rating on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Evotec in a research note on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $7.00.
View Our Latest Research Report on Evotec
Hedge Funds Weigh In On Evotec
Several institutional investors have recently bought and sold shares of the company. ABC Arbitrage SA increased its position in Evotec by 319.7% in the fourth quarter. ABC Arbitrage SA now owns 554,287 shares of the company’s stock worth $1,707,000 after buying an additional 422,230 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Evotec by 25.7% during the 4th quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company’s stock valued at $5,536,000 after buying an additional 367,545 shares during the last quarter. DCF Advisers LLC grew its stake in shares of Evotec by 48.3% during the 2nd quarter. DCF Advisers LLC now owns 1,114,493 shares of the company’s stock worth $4,681,000 after acquiring an additional 362,914 shares during the period. Pitcairn Co. purchased a new stake in Evotec in the 2nd quarter worth about $1,097,000. Finally, Jane Street Group LLC bought a new stake in Evotec in the 4th quarter valued at about $565,000. Hedge funds and other institutional investors own 5.81% of the company’s stock.
Evotec Stock Performance
EVO traded down $0.10 during midday trading on Friday, hitting $2.31. The company had a trading volume of 152,215 shares, compared to its average volume of 175,397. The stock’s 50 day moving average price is $3.43 and its 200 day moving average price is $3.44. Evotec has a 52 week low of $2.31 and a 52 week high of $4.80. The company has a current ratio of 2.12, a quick ratio of 2.03 and a debt-to-equity ratio of 0.48.
Evotec Company Profile
Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.
Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.